DiaMedica
Minneapolis
About DiaMedica
DiaMedica is a biopharmaceutical company that focuses on developing treatments for stroke and other vascular diseases where no current therapies are available. The company's treatments primarily focus on on chronic kidney disease and acute ischemic stroke. Its pipeline product, DM199, is a recombinant form of human tissue kallikrein-1.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $167.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:DMAC
- Website: diamedica.com
- Phone: (763)270-0603
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/diamedica-15666 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.